Outcomes of osimertinib in non-small-cell lung cancer and acquired EGFR Thr790Met mutation

Future development strategies for osimertinib may be dictated by difference in resistance mechanisms
Future development strategies for osimertinib may be dictated by difference in resistance mechanisms